Replimune Group, Inc. (REPL) is a publicly traded Healthcare sector company. As of May 21, 2026, REPL trades at $5.13 with a market cap of $413.69M and a P/E ratio of -1.65. REPL moved +9.57% today. Year to date, REPL is -38.72%; over the trailing twelve months it is -43.85%. Its 52-week range spans $1.50 to $17.00. Analyst consensus is sell with an average price target of $2.25. Rallies surfaces REPL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Replimune Presents 3-Year Survival and RP2 Phase 1 Safety Data at ASCO: Replimune secured two ASCO oral sessions presenting a three-year overall survival analysis of RP1 plus nivolumab in anti-PD-1 resistant melanoma and safety data from its RP2 phase 1 trial. Four posters will detail intratumoral RP1/RP2 safety and randomized RP2 combination trials in metastatic uveal melanoma, advanced melanoma and liver cancers.
| Metric | Value |
|---|---|
| Price | $5.13 |
| Market Cap | $413.69M |
| P/E Ratio | -1.65 |
| EPS | $-3.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.00 |
| 52-Week Low | $1.50 |
| Volume | 11.46K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-247.30M |
| Gross Margin | 0.00% |
7 analysts cover REPL: 0 strong buy, 0 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is sell. Average price target: $2.25.